See risks and benefits. Learn about the indications for SUTENT® (sunitinib malate) on the official patient website.

Sunitinib, sold under the brand name Sutent, is an anti-cancer medication. [2] It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib -resistant gastrointestinal stromal tumor (GIST) in January 2006.

2024年11月29日 · Sutent is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Sutent is a prescription medicine used to treat certain types of advanced or progressive tumors of the stomach, intestines, esophagus, pancreas, or kidneys.

舒尼替尼（Sunitinib，Sutent）是一种新型多靶向性的治疗肿瘤的口服药物。 舒尼替尼的首要开发目标为，用于治疗对标准疗法没有响应或不能耐受之胃肠道基质肿瘤和转移性肾细胞癌。

SUTENT® (sunitinib malate) medication page for patients to search for scientific information on Pfizer medications. Also, find the prescribing information, announcements, resources, and channels to connect with Pfizer Medical Information.

1.4 Advanced Pancreatic Neuroendocrine Tumors (pNET) SUTENT is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable...

通用名： 苹果酸舒尼替尼胶囊 商品名： 索坦 ® /SUTENT ® 英文名： Sunitinib Malate Capsules 汉语拼音： Pingguosuan Shunitini JiaoNang

SUTENT® (sunitinib malate) Medication Guide This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised: August 2021 MEDICATION GUIDESUTENT (su TENT) (sunitinib malate)capsules What is the most important information I should know about SUTENT?SUTENT

舒尼替尼 （INN： Sunitinib），商标名 索坦 （Sutent），是一种口服的小分子多靶点 受体酪氨酸激酶 抑制剂，2006年1月26日被 FDA 批准用于治疗对标准疗法没有响应或不能耐受的 胃肠道基质肿瘤 和转移性 肾细胞癌。

2021年9月8日 · Sunitinib is a kinase inhibitor present in SUTENT capsules as the malate salt. Sunitinib malate is described chemically as (2S)-2-hydroxybutanedoic acid with ...